{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:37:06Z","timestamp":1794620226631,"version":"4.9.1"},"reference-count":36,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"unspecified","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","award":["Grant no - NA"],"award-info":[{"award-number":["Grant no - NA"]}],"id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2026,2,16]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Selective inhibition of interleukin (IL)-23 through antagonism of the IL-23p19 subunit has demonstrated clinical efficacy in inflammatory bowel disease, but the molecular changes underlying the efficacy outcomes have not yet been described. Here, we provide a detailed evaluation of the cellular and molecular changes associated with guselkumab treatment in patients with moderately to severely active ulcerative colitis (UC) from the QUASAR Phase IIb induction study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this double-blind, placebo-controlled, dose-ranging induction study, patients (n=313) were randomised (1:1:1) to receive intravenous guselkumab 200 or 400 mg or placebo at weeks 0, 4, and 8. Colon biopsy samples were collected at weeks 0 and 12, enabling molecular profiling by bulk RNA sequencing (RNA-seq, n=257), single-cell RNA sequencing (n=52), and flow cytometry (n=30). Serum proteomic profiling was also performed at weeks 0, 4, and 12 (n=302).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Guselkumab treatment significantly reduced pro-inflammatory serum proteins by week 4 with continued decline through week 12, compared with placebo. Unsupervised analysis of tissue gene modules revealed significant changes in transcriptional states related to pro-inflammatory and epithelial repair pathways, which were most pronounced in patients who achieved histological-endoscopic mucosal improvement (HEMI) at week 12, an important tissue-based end point. Single-cell analyses supported a decrease in the cellular abundance of pro-inflammatory and an increase in mucosal cell types in tissue following treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This analysis of guselkumab in UC demonstrated changes in key pathways and cell types that are associated with achieving important clinical end points including HEMI at week 12.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04033445\">NCT04033445<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjgast-2025-002153","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T16:10:15Z","timestamp":1774282215000},"page":"e002153","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Multiomic characterisation of the clinical efficacy of guselkumab induction therapy in ulcerative colitis"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct04033445","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04033445","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Amy","family":"Hart","sequence":"first","affiliation":[{"name":"Immunology Translational Sciences & Medicine, Johnson and Johnson Limited, New Brunswick, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunandini","family":"Sridhar","sequence":"additional","affiliation":[{"name":"Immunology Translational Sciences & Medicine, Johnson and Johnson Limited, New Brunswick, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Venkat","sequence":"additional","affiliation":[{"name":"Immunology Translational Sciences & Medicine, Johnson and Johnson Limited, New Brunswick, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae","family":"Lee","sequence":"additional","affiliation":[{"name":"Immunology Translational Sciences & Medicine, Johnson and Johnson Limited, New Brunswick, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J","family":"Rusbuldt","sequence":"additional","affiliation":[{"name":"Immunology Translational Sciences & Medicine, Johnson and Johnson Limited, New Brunswick, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Richards","sequence":"additional","affiliation":[{"name":"Immunology Translational Sciences & Medicine, Johnson and Johnson Limited, New Brunswick, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Sisk","sequence":"additional","affiliation":[{"name":"Immunology Translational Sciences & Medicine, Johnson and Johnson Limited, New Brunswick, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Horowitz","sequence":"additional","affiliation":[{"name":"Immunology Translational Sciences & Medicine, Johnson and Johnson Limited, New Brunswick, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Tomsho","sequence":"additional","affiliation":[{"name":"Immunology Translational Sciences & Medicine, Johnson and Johnson Limited, New Brunswick, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun K","family":"Kannan","sequence":"additional","affiliation":[{"name":"Immunology Translational Sciences & Medicine, Johnson and Johnson Limited, New Brunswick, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Ruane","sequence":"additional","affiliation":[{"name":"Immunology Translational Sciences & Medicine, Johnson and Johnson Limited, New Brunswick, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Van den Berge","sequence":"additional","affiliation":[{"name":"Statistics and Decision Sciences, Johnson and Johnson Limited, New Brunswick, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T","family":"Rubin","sequence":"additional","affiliation":[{"name":"Medicine Inflammatory Bowel Disease Center, University of Chicago, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce E","family":"Sands","sequence":"additional","affiliation":[{"name":"Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"De Hertogh","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, University Hospitals Leuven, Leuven, Belgium"},{"name":"Department of Imaging & Pathology, Laboratory of Translational Cell & Tissue Research, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Hsiang G","family":"Huang","sequence":"additional","affiliation":[{"name":"Immunology Clinical Development, Johnson and Johnson Limited, New Brunswick, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Germinaro","sequence":"additional","affiliation":[{"name":"Immunology Clinical Development, Johnson and Johnson Limited, New Brunswick, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Cua","sequence":"additional","affiliation":[{"name":"Immunology Clinical Development, Johnson and Johnson Limited, New Brunswick, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Waterworth","sequence":"additional","affiliation":[{"name":"Immunology Translational Sciences & Medicine, Johnson and Johnson Limited, New Brunswick, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom C","family":"Freeman","sequence":"additional","affiliation":[{"name":"Immunology Translational Sciences & Medicine, Johnson and Johnson Limited, New Brunswick, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion L","family":"Vetter","sequence":"additional","affiliation":[{"name":"Immunology Clinical Development, Johnson and Johnson Limited, New Brunswick, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradford","family":"McRae","sequence":"additional","affiliation":[{"name":"Immunology Translational Sciences & Medicine, Johnson and Johnson Limited, New Brunswick, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3898-7093","authenticated-orcid":false,"given":"Bram","family":"Verstockt","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium"},{"name":"Department of Chronic Diseases and Metabolism, Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9741-9067","authenticated-orcid":false,"given":"Patrick","family":"Branigan","sequence":"additional","affiliation":[{"name":"Immunology Translational Sciences & Medicine, Johnson and Johnson Limited, New Brunswick, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"2026032309100600000_13.1.e002153.1","article-title":"Pathological mechanism and targeted drugs of ulcerative colitis: A review","volume":"102","author":"Guo","year":"2023","journal-title":"Medicine (Abingdon)"},{"key":"2026032309100600000_13.1.e002153.2","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1053\/j.gastro.2022.01.023","article-title":"What Does Disease Progression Look Like in Ulcerative Colitis, and How Might It Be Prevented?","volume":"162","author":"Krugliak Cleveland","year":"2022","journal-title":"Gastroenterology"},{"key":"2026032309100600000_13.1.e002153.3","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.031"},{"key":"2026032309100600000_13.1.e002153.4","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1053\/j.gastro.2020.08.037","article-title":"Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis","volume":"159","author":"Li","year":"2020","journal-title":"Gastroenterology"},{"key":"2026032309100600000_13.1.e002153.5","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjad212.0295","article-title":"P165 Guselkumab binding to CD64+ IL-23\u2013producing myeloid cells enhances potency for neutralizing IL-23 signaling","volume":"18","author":"Atreya","year":"2024","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"2026032309100600000_13.1.e002153.6","doi-asserted-by":"crossref","DOI":"10.14309\/01.ajg.0001034332.56167.db","article-title":"S1241\u2003Guselkumab Binding to CD64+ IL-23\u2013Producing Myeloid Cells Enhances Potency for Neutralizing IL-23 Signaling","volume":"119","author":"Allegretti","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2026032309100600000_13.1.e002153.7","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.08.038"},{"key":"2026032309100600000_13.1.e002153.8","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3519"},{"key":"2026032309100600000_13.1.e002153.9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1010310","article-title":"Graphia: A platform for the graph-based visualisation and analysis of high dimensional data","volume":"18","author":"Freeman","year":"2022","journal-title":"PLoS Comput Biol"},{"key":"2026032309100600000_13.1.e002153.10","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3947"},{"key":"2026032309100600000_13.1.e002153.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.06.029"},{"key":"2026032309100600000_13.1.e002153.12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.2517-6161.1982.tb01195.x","article-title":"The Statistical Analysis of Compositional Data","volume":"44","author":"Aitchison","year":"1982","journal-title":"Journal of the Royal Statistical Society Series B"},{"key":"2026032309100600000_13.1.e002153.13","doi-asserted-by":"crossref","unstructured":"Assefa AT , Verbist B , Van den Berge K . Assessing differential cell composition in single-cell studies using voomclr. Bioinformatics [Preprint]. doi:10.1101\/2024.09.12.612645","DOI":"10.1101\/2024.09.12.612645"},{"key":"2026032309100600000_13.1.e002153.14","doi-asserted-by":"crossref","first-page":"i251","DOI":"10.1093\/ecco-jcc\/jjad212.0138","article-title":"P008 Machine learning derived histological features of epithelial injury and repair in Ulcerative Colitis biopsies correlate with disease severity","volume":"18","author":"Griffin","year":"2024","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"2026032309100600000_13.1.e002153.15","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(23)03064-0","article-title":"Mo1754 MACHINE LEARNING-BASED PREDICTION OF GEBOES SCORE AND HISTOLOGIC IMPROVEMENT AND REMISSION THRESHOLDS IN ULCERATIVE COLITIS","volume":"164","author":"Gait\u00e1n","year":"2023","journal-title":"Gastroenterology"},{"key":"2026032309100600000_13.1.e002153.16","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-326451"},{"key":"2026032309100600000_13.1.e002153.17","doi-asserted-by":"crossref","DOI":"10.1172\/JCI173835","article-title":"Intercellular interaction between FAP+ fibroblasts and CD150+ inflammatory monocytes mediates fibrostenosis in Crohn\u2019s disease","volume":"134","author":"Ke","year":"2024","journal-title":"J Clin Invest"},{"key":"2026032309100600000_13.1.e002153.18","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-0992-y"},{"key":"2026032309100600000_13.1.e002153.19","doi-asserted-by":"crossref","first-page":"S874","DOI":"10.14309\/01.ajg.0000954208.38872.e1","article-title":"S1142\u2003Impact of Guselkumab Therapy on Histologic and Combined Histologic and Endoscopic Outcomes in Patients With Moderately to Severely Active Ulcerative Colitis: Week 12 Results From the Phase 3 QUASAR Induction Study","volume":"118","author":"Pan\u00e9s","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2026032309100600000_13.1.e002153.20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.4049\/immunohorizons.2300003","article-title":"Guselkumab More Effectively Neutralizes Psoriasis-Associated Histologic, Transcriptomic, and Clinical Measures than Ustekinumab","volume":"7","author":"Campbell","year":"2023","journal-title":"Immunohorizons"},{"key":"2026032309100600000_13.1.e002153.21","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001679","article-title":"Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials","volume":"7","author":"Sweet","year":"2021","journal-title":"RMD Open"},{"key":"2026032309100600000_13.1.e002153.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.09.003"},{"key":"2026032309100600000_13.1.e002153.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.08.019"},{"key":"2026032309100600000_13.1.e002153.24","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4307"},{"key":"2026032309100600000_13.1.e002153.25","doi-asserted-by":"publisher","DOI":"10.7417\/CT.2018.2085"},{"key":"2026032309100600000_13.1.e002153.26","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/964131","article-title":"Matrix metalloproteinases in inflammatory bowel disease: an update","volume":"2015","author":"O\u2019Sullivan","year":"2015","journal-title":"Mediators Inflamm"},{"key":"2026032309100600000_13.1.e002153.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2015.10.008"},{"key":"2026032309100600000_13.1.e002153.28","doi-asserted-by":"crossref","unstructured":"Cutilli A , Jansen SA , Paolucci F , et al . IFN\u03b3 induces epithelial reprogramming driving CXCL11-mediated T cell migration. bioRxiv 2024. doi:10.1101\/2024.02.03.578580","DOI":"10.1101\/2024.02.03.578580"},{"key":"2026032309100600000_13.1.e002153.29","doi-asserted-by":"crossref","first-page":"S623","DOI":"10.14309\/01.ajg.0000953016.91904.06","article-title":"S844\u2003Early Symptomatic Improvement With Guselkumab Induction Treatment in Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study","volume":"118","author":"Lichtenstein","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2026032309100600000_13.1.e002153.30","doi-asserted-by":"crossref","DOI":"10.14309\/01.ajg.0000953892.59221.8e","article-title":"S1063\u2003Improvement in Inflammatory Biomarker Levels Through Week 12 in Moderately to Severely Active Ulcerative Colitis Patients Treated With Guselkumab: Results From the Phase 3 QUASAR Induction Study","volume":"118","author":"Hisamatsu","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2026032309100600000_13.1.e002153.31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0140-6736(24)01927-5","article-title":"Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies","volume":"405","author":"Rubin","year":"2025","journal-title":"The Lancet"},{"key":"2026032309100600000_13.1.e002153.32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3001532","article-title":"Colon stroma mediates an inflammation-driven fibroblastic response controlling matrix remodeling and healing","volume":"20","author":"Jasso","year":"2022","journal-title":"PLoS Biol"},{"key":"2026032309100600000_13.1.e002153.33","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S318327"},{"key":"2026032309100600000_13.1.e002153.34","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.301"},{"key":"2026032309100600000_13.1.e002153.35","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adg7549","article-title":"Gut-associated lymphoid tissue attrition associates with response to anti-\u03b14\u03b27 therapy in ulcerative colitis","volume":"9","author":"Canales-Herrerias","year":"2024","journal-title":"Sci Immunol"},{"key":"2026032309100600000_13.1.e002153.36","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20220538","article-title":"Remodeling of colon plasma cell repertoire within ulcerative colitis patients","volume":"220","author":"Scheid","year":"2023","journal-title":"J Exp Med"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2025-002153","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T16:10:18Z","timestamp":1774282218000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2025-002153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,23]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/bmjgast-2025-002153"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2025-002153","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}